#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Beth Thomas Email
VP, Medicinal Chemistry . Storm Therapeutics
Cambridge,
Locationb**********@stormtherapeutics.com
Primary EmailHow to contact Beth Thomas
Join and see Beth's contact info for free!Current Roles
Employees:
48Revenue:
$7.4MAbout
STORM Therapeutics (www.stormtherapeutics.com) is a spin out company translating the groundbreaking work in RNA epigenetics of Prof Tony Kouzarides and Prof Eric Miska of the Gurdon Institute, University of Cambridge into the discovery of first in class drugs in oncology and other diseases Several large families of RNA-modifying enzymes have been identified that impact key biological processes by changing the activity of RNA through catalysing epigenetic RNA modifications. Advances in the understanding of RNA modification and its role in the development of cancer offer the prospect of exploring novel therapeutic targets and potential discovery and development of first-in-class products. STORM is working at the forefront of this new field. The company draws on its unique insights to develop candidate drug molecules for the treatment of specific cancers with high unmet medical need. Since inception in May 2015, Storm has raised over $50m in funding. Storm is backed by blue chip investors Merck Ventures, Pfizer Ventures, IP Group, Cambridge Innovation Capital, Seroba and Taiho Ventures, who share the founders' ambitions to build a world leading company in the field. The company occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK.Storm Therapeutics Address
Babraham Research CampusCambridge, null